Replies to post #1745 on Entremed (ENMD)

[squittman]

EntreMed will be presenting three abstracts at the upcoming Antiangiogenesis conference over the weekend beginning Friday, February 11. One abstract is on the new Panzem NCD, already in cancer trials for human patients. Another abstract is on the upcoming new anti-cancer vaccine which EntreMed will place into Phase I trials following an IND announcement in the next few months. And the third abstract is about EntreMed's new Panzem analogue 833, which has been reported to yield greater effectiveness, greater bioavailability and similar pharmacokinetics to Panzem itself, along with no increase in toxicity levels. EntreMed has already said that an announcement about Panzem analogue 833 will be forthcoming in
"early 2005." Would this antiangiogenesis conference be an appropriate place to introduce this new analogue, and would accompanying press releases, not only about the analogue but also about Panzem NCD and the anti-cancer vaccine, be logical sometime late this week or early next week? Stay tuned. Panzem is here. EntreMed is back. Dr. Steve